Although Jakafi has been approved for patients with higher-risk myelofibrosis, those with lower-risk disease may also benefit ...

Ruxolitinib can cause cytopenia, the most prominent adverse event (AE). There are rates of anemia and thrombocytopenia in ...

A review by authors from China examines evidence involving different treatment approaches. When ruxolitinib (Jakafi, Incyte) is given to patients with myelofibrosis in the period before and after ...

Vonjo was also shown to improve overall survival in patients with myelofibrosis treated with Vonjo in the real-world setting.

Using NGS in prognostic assessments enhances myelofibrosis prognosis and survival estimates, representing a step toward personalized medicine in myelofibrosis.

GSK's cancer unit has been given a fillip by the FDA with a broader-than-expected approval for JAK inhibitor momelotinib for anaemia associated with myelofibrosis, acquired as part of its $1.9 ...

DISC-0974 is a monoclonal antibody commercialized by Disc Medicine, with a leading Phase II program in Anemia in Chronic Kidney Disease (Renal Anemia).

整理丨小隐2024年欧洲肿瘤内科学会（ESMO）年会将于9月13日-17日在西班牙巴塞罗那召开。作为全球规模最大、学术水平最高、最具权威的临床肿瘤学会议之一，诸多重磅研究的最新结果将于会上发布。近日，ESMO年会摘要标题重磅公布，小编特此整理“中国之声 ...

The study commencement is based on previous clinical safety and efficacy data, along with robust preclinical evidence.

It can be used in both markets in patients with primary myelofibrosis, post-polycythaemia vera myelofibrosis, or post-essential thrombocythaemia myelofibrosis. In the pivotal MOMENTUM clinical ...

Risky but with rewards, Australian pharmaceutical companies developing treatments for rare diseases are competing for ...

Truist Securities has downgraded Incyte Corporation (NASDAQ:INCY), noting Jakafi’s (ruxolitinib) patent loss approaching in ...